![[인도 정품 리벨서스 소식 공유] New oral diabetes and obesity drug sale doubles in India amid demand surge](http://mitalmo.com/cdn/shop/articles/7f7a94186363f5ef216ee486f9ad8c2e.png?v=1725794694&width=3000)
기사 링크: https://www.business-standard.com/health/new-oral-diabetes-and-obesity-drug-sale-doubles-in-india-amid-demand-surge-124050900228_1.html
인도에서 리벨서스 정품은 2022년에 출시 되었고, 체중 감소 용도로써 수요가 급증했다는 기사입니다.
"Rybelsus, introduced in India in 2022 as an oral drug, is hailed as a breakthrough in Type 2 diabetes treatment. It is available in three strengths (3, 7, and 14 mg), and the monthly cost comes to approximately Rs 10,000."
인도에서는 리벨서스 때문에 비만치료제 시장이 거의 3배 가량 지난 2년간 성장했습니다.
surge in sales of anti-obesity medications, with the market tripling in two years, bouncing back from previous sluggish growth till 2021, according to Pharmarack.
"The anti-obesity market has itself tripled because of Rybelsus," ET quoted Sheetal Sapale, vice president of Commercial at Pharmarack, as saying.
리벨서스가 시장의 약 66% 를 차지하고 있다고 합니다.
Pharmarack data revealed that Semaglutide holds approximately 66 per cent of the value market share in the anti-obesity segment,
미녀와 탈모 리벨서스 구매대행 바로가기